Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8WXB1
UPID:
MT21A_HUMAN
Alternative names:
HSPA lysine methyltransferase; HSPA-KMT; Hepatocellular carcinoma-associated antigen 557b; Methyltransferase-like protein 21A
Alternative UPACC:
Q8WXB1; Q53RV0; Q8N1Z9; Q96GH6
Background:
Protein N-lysine methyltransferase METTL21A, also known as HSPA lysine methyltransferase, plays a pivotal role in post-translational modifications, specifically targeting the heat shock protein 70 (HSP70) family. It is responsible for the selective trimethylation of lysine residues in HSPA1, HSPA2, HSPA5, HSPA6, and HSPA8, which are crucial for cellular stress responses and protein homeostasis.
Therapeutic significance:
Understanding the role of Protein N-lysine methyltransferase METTL21A could open doors to potential therapeutic strategies. Its precise function in modulating the HSP70 family suggests a significant impact on cellular resilience and disease mechanisms.